These differences may be due to the lack of standardized methods for quantifying MKI67 expression, inter-tumor/intra-tumor heterogeneity, or the difference in patient population, such as racial or regional disparities (28, 30, 58–60). This evidence concerns the gene MKI67 and neoplasm.